William F. Hahne
Corporate Officer/Principal bei BIO-PATH HOLDINGS, INC.
Profil
William F.
Hahne is currently the Vice President-Clinical Research at Bio-Path Holdings, Inc. He previously worked as the Executive Director-Clinical Research at Eisai, Inc. from 1997 to 2002, Vice President-Clinical Development at CuraGen Corp.
from 2003 to 2005, VP-Clinical Development & Medical Affairs at Imunon, Inc. in 2006-2007, and Vice President-Medical at Vion Pharmaceuticals, Inc. He has an undergraduate degree from Grinnell College and a doctorate from Cornell University.
Aktive Positionen von William F. Hahne
| Unternehmen | Position | Beginn |
|---|---|---|
| BIO-PATH HOLDINGS, INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von William F. Hahne
| Unternehmen | Position | Ende |
|---|---|---|
| IMUNON, INC. | Chief Tech/Sci/R&D Officer | 01.12.2007 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | 01.01.2005 |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Chief Tech/Sci/R&D Officer | 01.01.2002 |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von William F. Hahne
| Grinnell College | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IMUNON, INC. | Health Technology |
| BIO-PATH HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
